WO2023001919 - USE OF BOSWELLIA FOR TREATING SARS-COV-2 INFECTION
National phase entry:
Publication Number
WO/2023/001919
Publication Date
26.01.2023
International Application No.
PCT/EP2022/070413
International Filing Date
20.07.2022
Title **
[English]
USE OF BOSWELLIA FOR TREATING SARS-COV-2 INFECTION
[French]
UTILISATION DE BOSWELLIA POUR LE TRAITEMENT D'UNE INFECTION PAR SARS-COV-2
Applicants **
VON KEUDELL, Christoph
Bellerivestrasse 29
8008 Zürich, CH
Inventors
VON KEUDELL, Christoph
Bellerivestrasse 29
8008 Zürich, CH
Priority Data
63/223,749
20.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1494 | |
| EPO | Filing, Examination | 4284 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 9652 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to the use of extracts from Boswellia species and pharmaceutical compositions comprising Boswellia extracts in the treatment of SARS-CoV-2 infection and related medical conditions.[French]
La présente invention concerne l'utilisation d'extraits de l'espèce Boswellia et des compositions pharmaceutiques comprenant des extraits de Boswellia dans le traitement d'une infection par le SARS-CoV-2 et d'états pathologiques associés.